HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report
HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–re...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001558 |
| _version_ | 1797342122504880128 |
|---|---|
| author | Aiko Ogimoto, MD Naoko Katsurada, MD, PhD Atsuhiko Yatani, MD Chihiro Mimura, MD Masatsugu Yamamoto, MD, PhD Motoko Tachihara, MD, PhD |
| author_facet | Aiko Ogimoto, MD Naoko Katsurada, MD, PhD Atsuhiko Yatani, MD Chihiro Mimura, MD Masatsugu Yamamoto, MD, PhD Motoko Tachihara, MD, PhD |
| author_sort | Aiko Ogimoto, MD |
| collection | DOAJ |
| description | HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs. |
| first_indexed | 2024-03-08T10:28:50Z |
| format | Article |
| id | doaj.art-bce36dd0c9184e7097e84cdfa1092f20 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-03-08T10:28:50Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-bce36dd0c9184e7097e84cdfa1092f202024-01-27T06:58:19ZengElsevierJTO Clinical and Research Reports2666-36432024-01-0151100612HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case ReportAiko Ogimoto, MD0Naoko Katsurada, MD, PhD1Atsuhiko Yatani, MD2Chihiro Mimura, MD3Masatsugu Yamamoto, MD, PhD4Motoko Tachihara, MD, PhD5Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanCorresponding author. Address for correspondence: Naoko Katsurada, MD, PhD, Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanHIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.http://www.sciencedirect.com/science/article/pii/S2666364323001558HIP1-ALKBRAF V600ELung adenocarcinomaResistance mechanismCase report |
| spellingShingle | Aiko Ogimoto, MD Naoko Katsurada, MD, PhD Atsuhiko Yatani, MD Chihiro Mimura, MD Masatsugu Yamamoto, MD, PhD Motoko Tachihara, MD, PhD HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report JTO Clinical and Research Reports HIP1-ALK BRAF V600E Lung adenocarcinoma Resistance mechanism Case report |
| title | HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report |
| title_full | HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report |
| title_fullStr | HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report |
| title_full_unstemmed | HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report |
| title_short | HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report |
| title_sort | hip1 alk rearranged lung cancer in a young adult with braf v600e mutation detected after alk tyrosine kinase inhibitor therapy a case report |
| topic | HIP1-ALK BRAF V600E Lung adenocarcinoma Resistance mechanism Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323001558 |
| work_keys_str_mv | AT aikoogimotomd hip1alkrearrangedlungcancerinayoungadultwithbrafv600emutationdetectedafteralktyrosinekinaseinhibitortherapyacasereport AT naokokatsuradamdphd hip1alkrearrangedlungcancerinayoungadultwithbrafv600emutationdetectedafteralktyrosinekinaseinhibitortherapyacasereport AT atsuhikoyatanimd hip1alkrearrangedlungcancerinayoungadultwithbrafv600emutationdetectedafteralktyrosinekinaseinhibitortherapyacasereport AT chihiromimuramd hip1alkrearrangedlungcancerinayoungadultwithbrafv600emutationdetectedafteralktyrosinekinaseinhibitortherapyacasereport AT masatsuguyamamotomdphd hip1alkrearrangedlungcancerinayoungadultwithbrafv600emutationdetectedafteralktyrosinekinaseinhibitortherapyacasereport AT motokotachiharamdphd hip1alkrearrangedlungcancerinayoungadultwithbrafv600emutationdetectedafteralktyrosinekinaseinhibitortherapyacasereport |